ANTISENSE PHARMA GmbH Announces Revised Development Path for Trabedersen
2/26/2013 11:14:38 AM
More...
|
ANTISENSE PHARMA GmbH Receives FDA Orphan Drug Designation for Trabedersen to Treat Malignant Melanoma
7/24/2012 9:52:34 AM
More...
|
ANTISENSE PHARMA GmbH Presents Trabedersen Phase I/II Complete Data at American Society of Clinical Oncology
6/4/2012 10:42:35 AM
More...
|
Dr. Philippe Calais Appointed Chief Executive Officer of ANTISENSE PHARMA GmbH
5/10/2012 6:25:45 AM
More...
|
ANTISENSE PHARMA GmbH Special Issue: Transforming Growth Factor Beta (TGF-ß) as a Target in Oncology
1/11/2012 10:02:31 AM
More...
|
ANTISENSE PHARMA GmbH Completes Round of Financing Worth Approximately 8 Million Euro - Founding Shareholders Facilitate the Participation of New Investors
7/6/2011 1:28:44 PM
More...
|
ANTISENSE PHARMA GmbH's Trabedersen Showed Excellent Safety Profile and First Signals of Encouraging Efficacy in Solid Tumors
6/7/2011 10:01:17 AM
More...
|
ANTISENSE PHARMA GmbH Release: Innovative Drug Development Covers More Than Just The Substance
6/1/2011 1:20:53 PM
More...
|
Meet ANTISENSE PHARMA GmbH at American Society of Clinical Oncology 2011
5/19/2011 10:32:17 AM
More...
|
ANTISENSE PHARMA GmbH Receives Approval for Clinical Studies in South Korea and Taiwan in Malignant Brain Tumors
2/2/2011 9:40:24 AM
More...
|
|